AYTU BIOPHARMA, INC Number of Reportable Segments
AYTU BIOPHARMA, INC (AYTU) reported Number of Reportable Segments of 100.00% for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-22.
Financial Statements › Notes › Segment Reporting
us-gaap:NumberOfReportableSegments · last filed 2026-09-22
- AYTU BIOPHARMA, INC number of reportable segments for the quarter ending 2025-09-30 was 100.00%.
- AYTU BIOPHARMA, INC number of reportable segments for the quarter ending 2021-09-30 was 200.00%, a 0.00% change year-over-year.
- AYTU BIOPHARMA, INC number of reportable segments for the quarter ending 2020-09-30 was 200.00%.
- AYTU BIOPHARMA, INC number of reportable segments for fiscal 2026 was 100.00%.
- AYTU BIOPHARMA, INC number of reportable segments for fiscal 2024 was 200.00%.
pure
| Period end | Number of Reportable Segments 3 month | Number of Reportable Segments 6 month | Number of Reportable Segments 9 month | Number of Reportable Segments 10 month | Number of Reportable Segments 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | 100.00% 10-K · filed 2026-09-22 | ||||
| 2026-03-31 | 100.00% 10-Q · filed 2026-05-13 | ||||
| 2025-09-30 | 100.00% 10-Q · filed 2026-02-03 | ||||
| 2024-06-30 | 200.00% 10-K · filed 2024-09-26 | ||||
| 2024-04-29 | 200.00% 10-K · filed 2024-09-26 | ||||
| 2024-03-31 | 200.00% 10-Q · filed 2024-05-15 | ||||
| 2023-12-31 | 200.00% 10-Q · filed 2024-02-14 | ||||
| 2021-09-30 | 200.00% 10-Q · filed 2021-11-15 | ||||
| 2020-12-31 | 200.00% 10-Q · filed 2021-05-17 | ||||
| 2020-09-30 | 200.00% 10-Q · filed 2021-11-15 |
Segments/Segment
| Period end | Number of Reportable Segments 12 month |
|---|---|
| 2018-06-30 | 2.00 Segments/Segment 10-K · filed 2018-09-06 |
segment
| Period end | Number of Reportable Segments 3 month | Number of Reportable Segments 6 month | Number of Reportable Segments 9 month | Number of Reportable Segments 12 month |
|---|---|---|---|---|
| 2023-09-30 | 2.00 segment 10-Q · filed 2023-11-14 | |||
| 2023-06-30 | 2.00 segment 10-K · filed 2023-10-12 | |||
| 2023-03-31 | 2.00 segment 10-Q · filed 2023-05-11 | 2.00 segment 10-Q · filed 2023-05-11 | ||
| 2022-12-31 | 2.00 segment 10-Q · filed 2023-02-21 | 2.00 segment 10-Q · filed 2023-02-21 | ||
| 2022-09-30 | 2.00 segment 10-Q · filed 2023-11-14 | |||
| 2022-06-30 | 2.00 segment 10-K · filed 2023-10-12 | |||
| 2022-03-31 | 2.00 segment 10-Q · filed 2023-05-11 | 2.00 segment 10-Q · filed 2023-05-11 | ||
| 2021-12-31 | 2.00 segment 10-Q · filed 2023-02-21 | 2.00 segment 10-Q · filed 2023-02-21 | ||
| 2021-09-30 | 2.00 segment 10-Q/A · filed 2023-02-21 | |||
| 2021-06-30 | 2.00 segment 10-K · filed 2022-09-27 | |||
| 2021-03-31 | 2.00 segment 10-Q · filed 2022-05-16 | 2.00 segment 10-Q · filed 2022-05-16 | ||
| 2020-12-31 | 2.00 segment 10-Q · filed 2022-02-14 | 2.00 segment 10-Q · filed 2022-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |